Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
The firm's tick-borne pathogens panel was also recently the subject of a clinical study, showing high accuracy in detecting numerous infectious agents.
The firm is also targeting a new market for oral fluid-based tests for drugs of abuse, projecting future growth due to new federal regulations.
A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service.
The firm plans to launch 10 new products next year, but analysts were cautious about Quidel's prospects moving forward.
Isothermal molecular assays to diagnose a parasitic infection that afflicts approximately 300 million people are moving closer to commercialization.
After years of frustration, researchers can now more definitively link a polio-like syndrome to prior infection with two common respiratory viruses.
The director of the Biomedical Advanced Research and Development Authority has launched two new funding programs in the past three years.
New outcomes data shows that the firm's test can help clinicians optimize antibiotic prescribing, but investment analysts have had mixed reactions.
Based in Warsaw, Poland, the technology was inspired by "ultra-fast" PCR methods from the Wittwer group and Scope plans to launch tests for MRSA and C. diff.
While the news of the BARDA contract drove a surge in T2's stock price, it was last month's NTAP decision that has company officials and analysts encouraged.
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.